Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000461.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172932567465984 |
|---|---|
| author | Nobukazu Fujimoto Katsuyuki Hotta |
| author_facet | Nobukazu Fujimoto Katsuyuki Hotta |
| author_sort | Nobukazu Fujimoto |
| collection | DOAJ |
| description | Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM. |
| format | Article |
| id | doaj-art-1695e0bffc864665a9c2af3f0287a0c0 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-1695e0bffc864665a9c2af3f0287a0c02024-11-09T00:30:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-05-018110.1136/jitc-2019-000461Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesotheliomaNobukazu Fujimoto0Katsuyuki Hotta1Department of Medical Oncology, Okayama Rosai Hospital, Okayama, JapanCenter of Innovative Clinical Medicine, Okayama University Hospital, Okayama, JapanPlatinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.https://jitc.bmj.com/content/8/1/e000461.full |
| spellingShingle | Nobukazu Fujimoto Katsuyuki Hotta Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma Journal for ImmunoTherapy of Cancer |
| title | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| title_full | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| title_fullStr | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| title_full_unstemmed | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| title_short | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| title_sort | current evidence and future perspectives of immune checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| url | https://jitc.bmj.com/content/8/1/e000461.full |
| work_keys_str_mv | AT nobukazufujimoto currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma AT katsuyukihotta currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma |